NEXPHORIA
Tirzepatide
Dual GIP/GLP-1 receptor agonist. FDA-approved metabolic research compound.
Purchase Type
Fresh cold-chain delivery every 30 days
Size
Format
For Research Use Only — Not For Human Consumption
This compound is sold exclusively for qualified research purposes. Not approved by the FDA for therapeutic use.
Certificate of Analysis Available
HPLC purity report, MS confirmation, batch documentation.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Eli Lilly, it received FDA approval in 2022 (Mounjaro) for type 2 diabetes and in 2023 (Zepbound) for chronic weight management. The molecule features a 39-amino acid backbone with a C20 fatty diacid modification enabling albumin binding and weekly dosing.
Complete Your Protocol
Related compounds.
Research Overview
Video: Research Background
Educational content from independent researchers and scientists. For research context only — not medical advice.
Research Overview
GLP-1 Receptor Agonists — Mechanisms of Action (Semaglutide, Tirzepatide)
Molecular Pharmacology
Scientific breakdown of GLP-1R and GIPR dual agonism in tirzepatide — covering both receptor signaling arms, incretin synergy, and SURMOUNT trial data context.
Side-by-Side Analysis
Compare Tirzepatide with Similar Compounds
View purity, MW, storage, and pricing side by side.
Frequently Bought Together
Complete Your Protocol
Researchers commonly order these compounds together. Convenient multi-compound ordering.
Weight Management
This itemTirzepatide
10mg
$120
Weight Management
RecommendedAOD-9604
5mg
$53
Weight Management
Semaglutide
5mg
$78
3 items selected
Uncheck any item to customize your bundle. Discount applied automatically at checkout.
Research Journal
Related Research Articles
Peptide Research for Metabolic Syndrome: Insulin Resistance, Hypertension, and Dyslipidemia Protocols
A comprehensive research guide to metabolic syndrome biology and multi-compound peptide protocols: GLP-1 agonist data from STEP 1 and SELECT, MOTS-c AMPK/ACC mechanism, AOD-9604 β3-AR lipolysis, and NAD+/SIRT1 lipogenesis suppression — with 5-component endpoint battery, 8-group study design, and reconstitution/storage guidance.
GLP-1 Agonists and Appetite Regulation: Hypothalamic Circuits, Ghrelin, and Hunger Endpoint Study Design
A mechanistic deep dive into how GLP-1 agonists suppress appetite through hypothalamic ARC/VMH circuits, ghrelin/GLP-1 axis interplay, gastric emptying, and reward pathway modulation — with validated hunger endpoints and study design for preclinical metabolic research.
Tirzepatide Lean Mass Preservation: GIPR, Body Composition, and Study Design
Why tirzepatide preserves lean mass better than semaglutide — GIPR adipose mechanism, SURMOUNT-1 body composition data, DIO rodent protocols, EchoMRI/DXA endpoints, and pair-fed study design.
Complete Your Protocol
Advanced Metabolic Stack
Tirzepatide's dual GLP-1/GIP agonism pairs with AOD-9604's fat metabolism pathway for comprehensive metabolic research.
Weight Management
Tirzepatide
10mg
$120
Weight Management
AOD-9604
5mg
$53